Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure

Cardiovascular Research

Volumn 87, Issue 1, 2010, Pages 30-39

  Westenbrink, B Daan ^a   Ruifrok, Willem Peter T ^a   Voors, Adriaan A ^a   Tilton, Ronald G ^b   Van Veldhuisen, Dirk J ^a   Schoemaker, Regien G ^a   Van Gilst, Wiek H ^a   De Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cardiac function; Erythropoietin; Heart failure; Neovascularization; Vascular endothelial growth factor

Indexed keywords

IMMUNOGLOBULIN G; MESSENGER RNA; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; VASCULOTROPIN; CARDIOTONIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN; STAT3 PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART PERFORMANCE; HUMAN; HUMAN CELL; MALE; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; FISCHER 344 RAT; GENETIC TRANSCRIPTION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; METABOLISM; NEWBORN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; STEM CELL; STEM CELL TRANSPLANTATION; TIME; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; CARDIOTONIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ERYTHROPOIETIN; HEART FAILURE; HUMANS; MALE; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; STEM CELL TRANSPLANTATION; STEM CELLS; TIME FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77955136355     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq041     Document Type: Article

References (31)

1. Anand IS, Florea VG. Traditional and novel approaches to management of heart failure: successes and failures. Cardiol Clin 2008;26:59-72.
2. de Boer RA, Pinto YM, van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-126.
3. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446: 444-448.
4. Westenbrink BD, de Boer RA, Voors AA, van Gilst WH, van Veldhuisen DJ. Anaemia in chronic heart failure: etiology and treatment options. Curr Opin Cardiol 2008;23: 141-147.
5. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA et al. Erythropoietin induces neovascularisation and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133.
6. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 2008;13:415-423.
7. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-2167.
8. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularisation. Eur Heart J 2007;28:2018-11027
9. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007;115: 2022-2032.
10. Imamura R, Moriyama T, Isaka Y, Namba Y, Ichimaru N, Takahara S et al. Erythropoie-tin protects the kidneys against ischemia reperfusion injury by activating hypoxia indu-cible factor-1alpha. Transplantation 2007;83:1371-1379.
11. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythro-poietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-1737.
12. Westenbrink BD, Oeseburg H, Kleijn L, van der Harst P, Belonje AM, Voors AA et al. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularisation only in the presence of local ischemia. Cardiovasc Drugs Ther 2008;22:265-274.
13. Maass AH, Buvoli M, Cardiomyocyte preparation culture, gene transfer. Methods Mol Biol 2007;366:321-330.
14. Muller Kobold AC, van Wijk RT, Franssen CF, Molema G, Kallenberg CG, Tervaert JW. In vitro up-regulation of E-selectin and induction of interleukin-6 in endo-thelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyan-giitis. Clin Exp Rheumatol 1999;17:433-440.
15. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990;63:115-122.
16. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118.
17. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997;99:2192-2202.
18. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-291.
19. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006;71:684-694.
20. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22-29.
21. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 2007;117:3176-3179.
22. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-5560.
23. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 2007;102:393-411.
24. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythro-poietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073-2080.
25. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angio-genic factor. Eur J Clin Invest 2003;33:891-896.
26. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H et al. Erythro-poietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 2005;68:299-306.
27. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii N et al. Important role of ery-thropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007;100:662-669.
28. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208-2216.
29. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anaemia. Circulation 2008;117:526-535.
30. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al. Derivatives of erythro-poietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
31. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 2008;79:611-620.